Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Louisville, Kentucky 40217


To establish the safety of alefacept when administered to adolescent subjects with moderate to severe psoriasis.

Study summary:

A planned interim analysis will be conducted to evaluate safety and pharmacokinetics following the Week 4 evaluation of approximately the first 12 subjects. A dose adjustment may be implemented based on these results. A preliminary review of the Week 4 pharmacokinetics of the first 6 subjects will occur to monitor exposure. If a dose adjustment is required, pharmacokinetics will be repeated for the first 12 subjects enrolled at the new dose (subjects 13-24).


Inclusion Criteria: - Subject has moderate to severe chronic plaque psoriasis involving at least 10% or greater body surface area - Subject is a candidate for systemic treatment or phototherapy - Subject is in good health and alefacept is not contraindicated - Subject must have absolute total CD4+ lymphocyte counts within the normal range at screening - Female subjects of child bearing potential have a negative pregnancy test prior to first dose of alefacept and agree to practice effective contraception during the study - Subject must have predosing laboratory findings without clinically significant abnormal values for hematocrit, hemoglobin, platelets, white blood count and differential, serum creatinine, bilirubin, ALT, AST and prothrombin. - Subject must have completed all standard childhood immunizations at least 12 weeks prior to the first dose - Subject meets medication washout requirements and agrees to follow medication restrictions during the study - Subject agrees to comply with the study requirements and agrees to come to the clinic for required study visits Exclusion Criteria: - Subject has a primary dermatological diagnosis of psoriasis other than plaque psoriasis - Subject has a known hypersensitivity to alefacept or any excipient of the study medication - Subject has had a serious local infection or systemic infection within 12 weeks prior to the first dose of study drug - Subject has a fever (body temperature ≥ 38°C [or > 37°C for sites in Latvia]) or symptomatic viral or bacterial infection (including upper respiratory tract infection) within 1 week prior to the first dose of study drug - Subject is known to be positive for HIV antibodies - Subject has a history of chronic serious infection including hepatic disease or has positive result to serology test for hepatitis A antibody IgM, hepatitis B surface antigen (HBsAg), hepatitis C virus (HCV) or human immunodeficiency virus (HIV) antibody or, in Europe, tubercle bacillus (TB) at Screening - Subject has a history or evidence of tuberculosis based on serology or a positive PPD skin test at Screening - Subject has had treatment with any immunosuppressant agent within 12 weeks, any antibody or immuno-globulin within 24 weeks, or any investigational drug or approved therapy for investigational use within 8 weeks prior to the first dose of study drug - Subject has had more than six herpes simplex virus (HSV) breakouts per year or is currently having an outbreak or has had an outbreak within the last 24 weeks - Subject has a history of malignancy (other than non-melanoma skin cancers) - Subject has a chronic condition which is not well controlled - Subject is pregnant or nursing - Subject has a history of severe allergic or anaphylactic reactions

Study is Available At:

Original ID:




Secondary ID:


Study Acronym:

Brief Title:

Safety and Pharmacokinetics (PK) of Alefacept in Adolescent Subjects With Moderate to Severe Psoriasis

Official Title:

A Phase 2, Single-Arm Study to Evaluate the Safety and Pharmacokinetics of Alefacept in Adolescent Subjects With Moderate to Severe Psoriasis [ISN 0485-CL-0004]

Overall Status:


Study Phase:

Phase 2



Minimum Age:

12 Years

Maximum Age:

17 Years

Quick Facts

Healthy Volunteers
Oversight Has DMC
Study Is FDA Regulated
Study Is Section 801
Has Expanded Access

Study Source:

Astellas Pharma Inc

Oversight Authority:

  • United States: Food and Drug Administration
  • Bulgaria: Bulgarian Drug Agency
  • Latvia: State Agency of Medicines

Reasons Why Stopped:

Study Type:


Study Design:

Allocation: Non-Randomized, Endpoint Classificatio

Number of Arms:


Number of Groups:


Total Enrollment:


Enrollment Type:


Overall Contact Information

Official Name:Vice President Medical Affairs
Study Director
Astellas Pharma Global Development

Study Dates

Start Date:April 2009
Completion Date:February 2012
Completion Type:Actual
Primary Completion Date:February 2012
Primary Completion Type:Actual
Verification Date:December 2013
Last Changed Date:December 10, 2013
First Received Date:December 11, 2008

Study Outcomes

Outcome Type:Secondary Outcome
Measure:Assessment of Pharmacokinetics through analysis of blood samples (only approximately first 24 subjects enrolled)
Time Frame:4 weeks
Safety Issues:False
Outcome Type:Secondary Outcome
Measure:Assessment of Pharmacodynamics: Total lymphocytes and lymphocyte subsets
Time Frame:4 Weeks
Safety Issues:False
Outcome Type:Primary Outcome
Measure:Assessment of Physical exams, vital signs, select blood chemistry and hematology, lymphocyte subset analysis, anti-alefacept antibody monitoring, adverse event monitoring including infections.
Time Frame:6 months
Safety Issues:False

Study Interventions

Intervention Type:Biological
Description:IM injection
Arm Name:1. alefacept
Other Name:Amevive

Study Arms

Study Arm Type:Experimental
Arm Name:1. alefacept

Study Agencies

Agency Class:Industry
Agency Type:Lead Sponsor
Agency Name:Astellas Pharma Inc

Sample and Retention Information

There are no available Sample and Retention Information

Study References

There are no available Study References

Data Source: ClinicalTrials.gov

Date Processed: January 21, 2020

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

This study is not currently recruiting Study Participants. The form below is not enabled.